Effects of stannous fluoride dentifrice on gingival health and oxidative stress markers: a prospective clinical trial.
Humans
Oxidative Stress
/ drug effects
Prospective Studies
Tin Fluorides
/ therapeutic use
Gingivitis
/ prevention & control
Female
Male
Adult
Saliva
/ chemistry
Periodontal Index
Dentifrices
/ therapeutic use
Gingival Crevicular Fluid
/ chemistry
Interleukin-6
/ analysis
C-Reactive Protein
/ analysis
Biomarkers
/ analysis
Protein Carbonylation
/ drug effects
Endotoxins
/ analysis
Antioxidants
/ therapeutic use
Middle Aged
L-Lactate Dehydrogenase
/ analysis
Dental Plaque
/ prevention & control
Lipoproteins, LDL
Follow-Up Studies
Young Adult
Clinical
Gingivitis
Oxidative stress
Stannous fluoride
Systemic health
Journal
BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684
Informations de publication
Date de publication:
30 Aug 2024
30 Aug 2024
Historique:
received:
06
05
2024
accepted:
20
08
2024
medline:
1
9
2024
pubmed:
1
9
2024
entrez:
30
8
2024
Statut:
epublish
Résumé
Periodontal disease results in oral dysbiosis, increasing plaque virulence and oxidative stress. Stannous fluoride (SnF This was a 2-month, single-center, single-treatment clinical trial. Twenty "disease" (> 20 bleeding sites with ≥ 3 pockets 3 mm-4 mm deep) and 20 "healthy" (≤ 3 bleeding sites with pockets ≤ 2 mm deep) adults were enrolled. All participants were instructed to use SnF The disease group showed statistically significant reductions in GBI at Month 1 (67%) and Month 2 (85%) and in MGI at Month 1 (36%) and Month 2 (51%) versus baseline (p < 0.001). At baseline, the disease group showed greater LDH in GCF and oxi-LDL levels in saliva versus the healthy group (p ≤ 0.01). Total antioxidant capacity (FRAP) in saliva increased versus baseline for the disease group at Months 1 and 2 (p < 0.05), and levels for the disease group were greater than the healthy group at both timepoints (p < 0.05). SnF SnF Clinicaltrials.gov NCT05326373, registered on 13/04/2022.
Sections du résumé
BACKGROUND
BACKGROUND
Periodontal disease results in oral dysbiosis, increasing plaque virulence and oxidative stress. Stannous fluoride (SnF
METHODS
METHODS
This was a 2-month, single-center, single-treatment clinical trial. Twenty "disease" (> 20 bleeding sites with ≥ 3 pockets 3 mm-4 mm deep) and 20 "healthy" (≤ 3 bleeding sites with pockets ≤ 2 mm deep) adults were enrolled. All participants were instructed to use SnF
RESULTS
RESULTS
The disease group showed statistically significant reductions in GBI at Month 1 (67%) and Month 2 (85%) and in MGI at Month 1 (36%) and Month 2 (51%) versus baseline (p < 0.001). At baseline, the disease group showed greater LDH in GCF and oxi-LDL levels in saliva versus the healthy group (p ≤ 0.01). Total antioxidant capacity (FRAP) in saliva increased versus baseline for the disease group at Months 1 and 2 (p < 0.05), and levels for the disease group were greater than the healthy group at both timepoints (p < 0.05). SnF
CONCLUSION
CONCLUSIONS
SnF
CLINICAL TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov NCT05326373, registered on 13/04/2022.
Identifiants
pubmed: 39215289
doi: 10.1186/s12903-024-04785-7
pii: 10.1186/s12903-024-04785-7
pmc: PMC11365164
doi:
Substances chimiques
Tin Fluorides
0
Dentifrices
0
Interleukin-6
0
C-Reactive Protein
9007-41-4
Biomarkers
0
Endotoxins
0
Antioxidants
0
L-Lactate Dehydrogenase
EC 1.1.1.27
Lipoproteins, LDL
0
IL6 protein, human
0
Banques de données
ClinicalTrials.gov
['NCT05326373']
Types de publication
Journal Article
Clinical Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1019Informations de copyright
© 2024. The Author(s).
Références
Am J Dent. 2018 Aug;31(4):184-188
pubmed: 30106533
J Biol Chem. 1986 Apr 5;261(10):4426-31
pubmed: 3007455
Curr Pharm Des. 2021;27(2):263-275
pubmed: 32679014
Nat Rev Drug Discov. 2021 Sep;20(9):689-709
pubmed: 34194012
Front Cell Infect Microbiol. 2016 Jan 05;5:92
pubmed: 26779447
Patholog Res Int. 2016;2016:5480267
pubmed: 26966611
Front Immunol. 2014 Sep 25;5:461
pubmed: 25309543
Front Biosci. 2008 Jan 01;13:966-84
pubmed: 17981604
Biomed J. 2019 Feb;42(1):27-35
pubmed: 30987702
J Clin Dent. 2018 Mar;29(1):1-12
pubmed: 29758151
J Periodontal Res. 2014 Feb;49(1):129-36
pubmed: 23710550
J Oral Pathol Med. 2015 Nov;44(10):884-7
pubmed: 25816896
Am J Dent. 2018 Aug;31(4):215-224
pubmed: 30106539
Dis Markers. 2017;2017:9547956
pubmed: 28337048
J Cell Physiol. 2018 Sep;233(9):6393-6400
pubmed: 29574949
J Biol Chem. 2019 Dec 20;294(51):19683-19708
pubmed: 31672919
J Biol Chem. 2004 Nov 19;279(47):48487-90
pubmed: 15337754
J Periodontal Res. 2018 Aug;53(4):487-494
pubmed: 29446092
Heliyon. 2019 Dec 09;5(12):e02850
pubmed: 31872105
Periodontol 2000. 2016 Feb;70(1):65-79
pubmed: 26662483
Clin Prev Dent. 1986 Jan-Feb;8(1):3-6
pubmed: 3485495
Periodontol 2000. 2007;43:160-232
pubmed: 17214840
J Clin Periodontol. 2005;32 Suppl 6:57-71
pubmed: 16128830
J Periodontal Res. 2010 Feb;45(1):1-7
pubmed: 20465752
Clin Chim Acta. 2003 Mar;329(1-2):23-38
pubmed: 12589963
J Cardiol. 2019 Jan;73(1):22-27
pubmed: 29907363
Microbiology (Reading). 2003 Feb;149(Pt 2):279-294
pubmed: 12624191
Periodontol 2000. 2022 Jun;89(1):19-40
pubmed: 35244966
J Clin Dent. 2016 Sep;27(3):84-89
pubmed: 28390203
J Clin Periodontol. 2022 Mar;49(3):270-279
pubmed: 34970759
Biol Chem. 2019 May 27;400(6):711-732
pubmed: 30864421
J Immunol Methods. 2011 Oct 28;373(1-2):19-25
pubmed: 21821037
Int Immunol. 2005 Jan;17(1):1-14
pubmed: 15585605
Oxid Med Cell Longev. 2020 Sep 15;2020:5245308
pubmed: 33014272
Int J Oral Sci. 2019 Nov 5;11(3):30
pubmed: 31685798
Age (Dordr). 2015 Jun;37(3):9781
pubmed: 25943699
Expert Rev Clin Immunol. 2023 Apr;19(4):405-415
pubmed: 36803467
J Clin Periodontol. 2019 Dec;46(12):1205-1216
pubmed: 31562774
J Hypertens. 2013 Nov;31(11):2251-8; discussion 2258
pubmed: 23868086
Immunology. 2022 Jan;165(1):22-43
pubmed: 34704249
Oxid Med Cell Longev. 2019 Mar 12;2019:1279250
pubmed: 30992736
Circulation. 2005 Aug 2;112(5):651-7
pubmed: 16043640
Exp Gerontol. 2014 Sep;57:122-31
pubmed: 24877899
Clin Biochem. 2019 Jun;68:1-8
pubmed: 30995442
Endocr Metab Immune Disord Drug Targets. 2020;20(6):855-868
pubmed: 31886754
J Periodontal Res. 1989 Jan;24(1):75-80
pubmed: 2524573